



Nathaniel F. Gray

ASSOCIATE

San Francisco

P +1 415 801 4922

Nate is a corporate and securities associate.

Nate represents start-up, emerging growth and public life sciences and technology companies and is passionate about working with companies that are developing scientific and technological innovations that will improve lives, transform business and tackle the world's biggest problems.

His practice spans the entire corporate lifecycle, from formation through liquidity, and he regularly serves as principal outside or general counsel to his clients. Nate is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, restructuring and spin-outs, general corporate and governance matters, M&A events and public offerings.

He also represents many of the leading seed, venture capital and growth equity investment funds in their investment transactions. Prior to joining Gunderson Dettmer, Nate was a private equity and mergers & acquisitions associate in the Boston and San Francisco offices of Ropes & Gray LLP.

Nate lives in the Bay Area with his wife and labradoodle, loves skiing, biking (mountain biking, gravel and road), and hiking.

Deal Highlights

General Corporate Counseling and Venture Financings

- Moonwalk Biosciences with its formation and \$57 million Series A Financing
- Radar Therapeutics in its \$13.4 million Series Seed financing
- BillionToOne in its \$130 million Series D financing, \$125 million Series C financing, \$48.5 million equity and \$35 million debt financing
- Alamar Biosciences in its \$128 million Series C financing, \$80 million Series B financing and spin-out of Attovia Therapeutics
- Neuron23 in its \$100 million Series C financing
- Ancora Biotech LLC in its formation and \$60 million Series A financing co-lead by Lightspeed Venture Partners and SR One
- Star Therapeutics LLC in its \$90 million Series C financing led by Sofinnova and spin-out of Electra Therapeutics
- Electra Therapeutics in its \$84 million Series B financing
- Pro Shop its formation, \$20 million Series A financing and partnership with the PGA Tour
- Imply Data in its \$100 million Series D financing

Growth Equity

- Healthquest Capital in its investment in American Oncology Network in connection with American Oncology Network's up-C reorganization and de-SPAC transaction
- PFM Health Sciences as lead investor in Metagenomi's \$175 million Series B financing
- Sixth Street Partners as lead investor in the \$830 million growth equity financing in Caris Life Sciences*
- Silver Lake Partners in its investment in Stripe*

- Silver Lake Partners in its \$400 million growth equity investment in EverCommerce*

Mergers & Acquisitions

- TeneoTwo in its sale, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, to Astazeneca for up to \$1.27 billion
- Miroculus in its sale to Integra Biosciences
- Gilead Sciences*, Inc. in:
 - its \$1.74 billion exclusive option to acquire Pionyr Immunotherapeutics Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Pionyr for \$275 million, an option for Gilead to acquire the remaining equity interests of Pionyr for \$315 million, and up to \$1.15 billion of potential future milestone payments to Pionyr equityholders
 - its \$1.55 billion exclusive option to acquire Tizona Therapeutics, Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Tizona for \$300 million, and an option for Gilead to acquire the remaining equity interests of Tizona for up to \$1.25 billion of potential option fees and future milestone payments to Tizona equityholder
 - its \$30 million PIPE investment in Gristone Oncology, Inc. (Nasdaq: GRTS) in connection with a collaboration, option and license agreement
- TPG in its acquisition of Entertainment Partners*
- Altamont Capital Partners in:
 - its carve-out acquisition of Publicis Healthcare Solutions*
 - its sale of OMNIPLEX Worldwide Services Corporation to Constellis*

*Representation completed prior to joining Gunderson Dettmer.

Credentials

EDUCATION

- Boston University School of Law, J.D.
magna cum laude
Edward F. Hennessey Distinguished Scholar
Paul J. Liacos Scholar
- Kenyon College, B.A., Political Science
cum laude

BAR ADMISSIONS

- California
- Massachusetts

Focus Areas

Corporate Governance & Strategy
Mergers & Acquisitions
Fund Investments in Companies
Public Companies/Public Offerings
Seed, Venture and Growth Financings
Life Sciences

Related News & Insights

CLIENT NEWS

Monarch Tractor Announces \$133M Series C Financing

CLIENT NEWS

A16z Leads \$175M Series B Financing of Saronic

CLIENT NEWS

BillionToOne Announces \$130M Series D

CLIENT NEWS

Liminal Announces \$5M Seed Led by Fin Capital

CLIENT NEWS

Radar Therapeutics Announces \$13.4M Seed financing

CLIENT NEWS

RevenueCat Announces \$12M Series C Financing to Expand to New Markets

CLIENT NEWS

Pro Shop Announces \$20M Series A and Partnership With PGA and Elysian Park Ventures

CLIENT NEWS

Alamar Biosciences Announces \$128M Series C to Accelerate Commercialization of its Proteomics Platform

CLIENT NEWS

Moonwalk Biosciences Launches with \$57M in Financing to Advance a New Class of Precision Epigenetic Medicines

CLIENT NEWS

Star Therapeutics Announces \$90M Series C Financing Led by Sofinnova

CLIENT NEWS

Miroculus Acquired by INTEGRA Biosciences

CLIENT NEWS

BillionToOne Announces \$48.5M Equity and \$35M Debt Financing for Next-Gen Molecular Diagnostics

CLIENT NEWS

Software Developer Better Stack Announces its \$18.6M Series A Financing